Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells associate with clinical outcomes in NHL Running Head: Polyfunctional CAR T cell-associated clinical outcomes

[1]  Alaina Kaiser,et al.  Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response , 2017, Journal of Immunotherapy for Cancer.

[2]  J. Friedberg,et al.  Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Heimfeld,et al.  Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells , 2016, Science Translational Medicine.

[4]  G. Wertheim,et al.  Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. , 2016, Cancer discovery.

[5]  B. Jabri,et al.  IL-15 functions as a danger signal to regulate tissue-resident T cells and tissue destruction , 2015, Nature Reviews Immunology.

[6]  David L. Porter,et al.  Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia , 2015, Science Translational Medicine.

[7]  D. Pe’er,et al.  Highly multiplexed profiling of single-cell effector functions reveals deep functional heterogeneity in response to pathogenic ligands , 2015, Proceedings of the National Academy of Sciences.

[8]  S. Grupp,et al.  Engineered T cells for cancer therapy , 2014, Cancer Immunology, Immunotherapy.

[9]  Mario Roederer,et al.  Single-cell technologies for monitoring immune systems , 2014, Nature Immunology.

[10]  S. Rosenberg,et al.  Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors , 2013, Nature Reviews Clinical Oncology.

[11]  Michel Sadelain,et al.  The basic principles of chimeric antigen receptor design. , 2013, Cancer discovery.

[12]  David Baltimore,et al.  Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy. , 2013, Cancer discovery.

[13]  W. Wilson,et al.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.

[14]  S. Kern,et al.  Th17 cells are long lived and retain a stem cell-like molecular signature. , 2011, Immunity.

[15]  Y. Li,et al.  Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse , 2011, Journal of Clinical Neuroscience.

[16]  S. Rosenberg,et al.  CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma , 2010, Clinical Cancer Research.

[17]  W. Zou,et al.  TH17 cells in tumour immunity and immunotherapy , 2010, Nature Reviews Immunology.

[18]  E. Tolosa,et al.  Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. , 2009, Brain : a journal of neurology.

[19]  W. Wilson,et al.  Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor , 2009, Journal of immunotherapy.

[20]  M. Roederer,et al.  T-cell quality in memory and protection: implications for vaccine design , 2008, Nature Reviews Immunology.

[21]  I. Türbachova,et al.  DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3+ conventional T cells , 2007, European journal of immunology.

[22]  T. Waldmann.  The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design , 2006, Nature Reviews Immunology.

[23]  A. Zelenetz,et al.  Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. , 2003, Blood.

[24]  J. Sheridan,et al.  Requirement of MIP-1 alpha for an inflammatory response to viral infection. , 1995, Science.

[25]  K. Matsushima,et al.  Essential involvement of interleukin‐8 (IL‐8) in acute inflammation , 1994, Journal of leukocyte biology.